Show simple item record

AuthorMarei, Hany E.
AuthorAlthani, Asmaa
AuthorAfifi, Nahla
AuthorPozzoli, Giacomo
AuthorCaceci, Thomas
AuthorAngelini, Franco
AuthorCenciarelli, Carlo
Available date2023-03-27T10:16:10Z
Publication Date2021-09-01
Publication NameMolecular Biology Reports
Identifierhttp://dx.doi.org/10.1007/s11033-021-06630-4
CitationMarei, H.E., Althani, A., Afifi, N. et al. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches. Mol Biol Rep 48, 6513–6524 (2021). https://doi.org/10.1007/s11033-021-06630-4
ISSN03014851
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85112580652&origin=inward
URIhttp://hdl.handle.net/10576/41351
AbstractWe give a summary of SARS-genetic CoV-2’s structure and evolution, as well as current attempts to develop efficient vaccine and treatment methods for SARS-CoV-2 infection, in this article. Most therapeutic strategies are based on repurposing of existing therapeutic agents used against various virus infections and focused mainly on inhibition of the virus replication cycle, enhancement of innate immunity, and alleviation of CRS caused by COVID-19. Currently, more than 100 clinical trials on COVID-19 aim to provide robust evidence on the efficacy of the currently available anti-SARS-CoV-2 antiviral substances, such as the nucleotide analogue remdesivir, the antimalarial drug chloroquine, and drugs directed against docking of SARS-CoV-2 to the membrane-associated angiotensin-converting enzyme 2 (ACE2) such as transmembrane protease serine 2 (TMPRSS2). The current vaccination campaign is ongoing worldwide using different types of vaccines such as Pfizer-BioNTech and Moderna, Johnson & Johnson, Oxford-AstraZeneca, Novavax, and others with efficacy ranging from 72–95%. In March 2021 Germany limited the use of the Oxford-AstraZeneca COVID-19 vaccine to people 60 years of age and older due to concerns that it may be causing blood clots. Further study and more data are needed to confirm the safety of different available vaccines.
Languageen
PublisherSpringer
SubjectAntiviral agents
COVID-19 genomics
Therapeutic approach
Vaccine
TitlePandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches
TypeArticle Review
Pagination6513-6524
Issue Number9
Volume Number48
ESSN1573-4978
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record